Scientists find new drug target for hard-to-treat leukaemia
(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia a cancer with limited treatment options and relatively poor survival, according to research published in Cancer Cell today.
The team at the Paterson Institute for Cancer Research at The University of Manchester have identified a new drug target an enzyme called LSD1 for an aggressive form of acute myeloid leukaemia called mixed lineage leukaemia (MLL). LSD1 helps control whether certain cancer-causing genes are turned on or off. Blocking the enzyme prevents the production of proteins that drive the cancer.
Scientists at Cancer Research UKs Paterson Drug Discovery Unit synthesised molecules to block this enzyme, and lead author Dr Tim Somervaille, group leader at Cancer Research UKs Leukaemia Biology Laboratory, showed that they could stop the growth of leukaemia cells taken from patients with the disease, and also from mice.
Every year in the UK around 2,380 people are diagnosed with acute myeloid leukaemia and of these it is estimated that around five percent around 120 patients have the MLL subtype.
Survival for acute myeloid leukaemia remains low although it has improved. Currently, around forty percent of people aged under 60 with the MLL-AF9 subtype survive the disease for five years or more.
Dr Somervaille said: Its difficult to successfully treat patients with this type of leukaemia. There arent any targeted drugs available and many patients cant be cured with current treatments, such as intensive chemotherapy and bone marrow transplantation. So theres an urgent need for new drugs.
Were very pleased to have tested molecules that homes in on an enzyme called LSD1 in a completely new approach to stop the growth of this disease. And we also believe this target may be important in a range of other types of cancer, but more research is needed.
The next stage is to develop molecules like this one further, and run clinical trials to see if they could be used to treat patients in the future.
Dr Julie Sharp, Cancer Research UKs senior science information manager, said: Its great news that this molecule could provide a new targeted way to treat an aggressive type of leukaemia, for which treatment options are limited.
Our scientists have been at the heart of progress that has seen great improvements in the treatment of leukaemia. For example, we developed some of the first important drugs for blood cancers and pioneered treatment with radiotherapy. And weve revealed many of the gene changes that fuel the development and growth of blood cancers, paving the way for future treatments.
But there is much more to be done and, only with continued public support, can our scientists around the UK continue their groundbreaking research into leukaemia to learn more about the biology of the disease and improve survival.
More information: Harris, W. et al (2012). The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells Cancer Cell DOI: 10.1016/j.ccr.2012.03.014
Provided by Cancer Research UK
- Scientists discover how to beat resistance to standard leukaemia drug Dec 09, 2011 | not rated yet | 0
- Cancer Research UK launches trial of new drug to treat acute childhood leukaemia Jan 27, 2012 | not rated yet | 0
- Stem cell treatment to prevent leukemia returning is a step closer, say scientists Jun 02, 2011 | not rated yet | 0
- Key cause of bone marrow failure identified May 03, 2011 | not rated yet | 0
- Scientists reveal first 3D image of cancer prevention molecule Jan 23, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer 1 hour ago | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer 2 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer 2 hours ago | 5 / 5 (2) | 0
A leading expert in childhood cancer at The University of Nottingham is spearheading a Europe-wide lobby of the European Parliament to try to make it easier for doctors to develop and test new treatments on children and young ...
Cancer 3 hours ago | not rated yet | 0
(AP)—Researchers examining the incidence of brain cancer at jet engine manufacturer Pratt & Whitney in Connecticut say they have found no statistically significant elevations in the rate of cancer among workers.
Cancer 4 hours ago | not rated yet | 0
Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.
52 minutes ago | not rated yet | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
1 hour ago | 5 / 5 (1) | 0 |
New research presented today shows that formation of new neurons in the hippocampus - a brain region known for its importance in learning and remembering - could cause forgetting of old memories by causing a reorganization ...
1 hour ago | not rated yet | 0
Ernie Pyle – an iconic war correspondent in World War II – reportedly said "There are no atheists in foxholes." A new joint study between two brothers at Cornell and Virginia Wesleyan found that only ...
1 hour ago | 3 / 5 (1) | 0
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
1 hour ago | 3 / 5 (1) | 1
The individualisation of drug treatments to support patients to self-manage their conditions is a concept that sits at the heart of policy, but a recent study in BMJ Open shows that there is no concrete defini ...
1 hour ago | not rated yet | 0